drugset / Trial / NCT00953771

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

NCT00953771

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to find out if administration of danazol with plasma exchange and corticosteroids will reduce the number of plasma exchanges required to control Thrombotic Thrombocytopenic Purpura (TTP).

Timeline

Start
2008-10
Primary completion
2015-11-19
Completion
2015-11-19

Publications

  • Results Torri V, Friedman M, Shapira I, Patel AA, Yoe J, Shah VP, Mirzoyev T, Machuca M, Varma M. Phase II study of danazol with plasma exchange and corticosteroids for the treatment of thrombotic thrombocytopenic purpura. Blood (2023) 142 (Supplement 1): 4007.

Drugs

EvaluationDrugModalityDoseRoute
Subject Danazol Other / unclassified 600 mg Oral